应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
COR CENCORA
已收盘 05-08 16:00:00 EDT
283.77
-20.81
-6.83%
盘后
283.77
+0.00
0.00%
19:58 EDT
最高
303.13
最低
282.98
成交量
412.38万
今开
301.00
昨收
304.58
日振幅
6.62%
总市值
550.28亿
流通市值
518.55亿
总股本
1.94亿
成交额
11.94亿
换手率
2.26%
流通股本
1.83亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
花旗：维持Cencora(COR.US)评级，由买入调整至买入评级, 目标价由330.00美元调整至355.00美元。
金融界 · 05-08 19:23
花旗：维持Cencora(COR.US)评级，由买入调整至买入评级, 目标价由330.00美元调整至355.00美元。
Cencora, Inc.跌1.60% 股价跌破300美元大关
市场透视 · 05-08 13:42
Cencora, Inc.跌1.60% 股价跌破300美元大关
异动解读 | CENCORA盘中大涨5.06%，特药需求强劲推动业绩超预期
异动解读 · 05-07 14:12
异动解读 | CENCORA盘中大涨5.06%，特药需求强劲推动业绩超预期
东吴证券：一季度可比口径下险企NBV继续较快增长 产险COR显著改善
智通财经 · 05-02
东吴证券：一季度可比口径下险企NBV继续较快增长 产险COR显著改善
【研报掘金｜华泰证券：上调中国再保险目标价至1.1港元 去年盈利超预期】华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。
金融界 · 02-24
【研报掘金｜华泰证券：上调中国再保险目标价至1.1港元 去年盈利超预期】华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。
【沃尔格林联合博姿继续出售Cencora股份 套现约3亿美元】 美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）
金融界 · 02-07
【沃尔格林联合博姿继续出售Cencora股份 套现约3亿美元】 美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）
Cencora 第一季度财报：肥胖药物和特殊药品推动收入和每股收益超预期
财报速递 · 02-05
Cencora 第一季度财报：肥胖药物和特殊药品推动收入和每股收益超预期
Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。
金融界 · 02-05
Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。
Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿
财报速递 · 02-05
Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿
富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。
金融界 · 01-29
富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。
新旧会计准则切换：保险公司利润瞬间“变脸” 从巨亏10.87亿元到大赚11.11亿元
21世纪经济报道 · 2024-12-12
新旧会计准则切换：保险公司利润瞬间“变脸” 从巨亏10.87亿元到大赚11.11亿元
中国人保：COR承压NBV翻倍 投资拉动利润高增
证券市场周刊 · 2024-11-21
中国人保：COR承压NBV翻倍 投资拉动利润高增
Cencora, Inc.2024财年实现净利润15.09亿美元，同比减少13.52%
市场透视 · 2024-11-14
Cencora, Inc.2024财年实现净利润15.09亿美元，同比减少13.52%
Cencora, Inc.盘中异动 早盘股价大涨5.00%
市场透视 · 2024-11-06
Cencora, Inc.盘中异动 早盘股价大涨5.00%
【券商聚焦】国联证券维持中国财险(02328)“买入”评级 料车险执行“报行合一”有望带动COR同比改善
金吾财讯 · 2024-10-30
【券商聚焦】国联证券维持中国财险(02328)“买入”评级 料车险执行“报行合一”有望带动COR同比改善
里昂：升中国财险目标价至15.2港元 第三季业绩好坏参半
美港电讯 · 2024-10-30
里昂：升中国财险目标价至15.2港元 第三季业绩好坏参半
Cencora, Inc.盘中异动 急速上涨5.02%
市场透视 · 2024-10-15
Cencora, Inc.盘中异动 急速上涨5.02%
华创证券：下半年人身险NBV增长逻辑或有量价双驱机会 财险COR或同比好转
智通财经网 · 2024-09-20
华创证券：下半年人身险NBV增长逻辑或有量价双驱机会 财险COR或同比好转
【券商聚焦】国联证券维持中国财险(02328)“买入”评级 指COR有望延续向好
金吾财讯 · 2024-09-19
【券商聚焦】国联证券维持中国财险(02328)“买入”评级 指COR有望延续向好
【金色晚报 | 9月18日晚间重要动态一览】12:00-21:00关键词：Revolut、MicroStrategy、贝
金色财经 · 2024-09-18
【金色晚报 | 9月18日晚间重要动态一览】12:00-21:00关键词：Revolut、MicroStrategy、贝
加载更多
公司概况
公司名称：
CENCORA
所属市场：
NYSE
上市日期：
--
主营业务：
Cencora, Inc.是全球最大的药品采购和分销服务公司之一，帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品加强患者护理的机会。该公司提供创新计划和服务，旨在提高药品供应链在人类和动物健康方面的效力和效率。更具体地说，该公司向位于美国和部分全球市场的各种医疗保健提供商提供全面的品牌、专业品牌和非专利药品、非处方医疗产品、家庭医疗用品和设备以及相关服务，包括急性病医院和卫生系统、独立和连锁零售药店、邮购药房、诊所、长期护理和替代地点药房、医师执业、医疗和透析诊所、兽医和其他客户。此外，公司还为医疗保健提供商和制药制造商提供各种相关服务，包括数据分析、结果研究、报销和药物咨询服务、利基优质物流服务、库存管理、药房自动化、药房管理和包装解决方案。
发行价格：
--
{"stockData":{"symbol":"COR","market":"US","secType":"STK","nameCN":"CENCORA","latestPrice":283.77,"timestamp":1746734400000,"preClose":304.58,"halted":0,"volume":4123837,"hourTrading":{"tag":"盘后","latestPrice":283.77,"preClose":283.77,"latestTime":"19:58 EDT","volume":94871,"amount":26921818.4224,"timestamp":1746748722449},"delay":0,"floatShares":182734698,"shares":193917082,"eps":7.021558,"marketStatus":"已收盘","change":-20.81,"latestTime":"05-08 16:00:00 EDT","open":301,"high":303.13,"low":282.98,"amount":1193927844.77516,"amplitude":0.066157,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":7.021558,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746777600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1285214400000,"exchange":"NYSE","adjPreClose":304.58,"dividendRate":0.007471,"preHourTrading":{"tag":"盘前","latestPrice":305.39,"preClose":304.58,"latestTime":"09:29 EDT","volume":566,"amount":172575.5225,"timestamp":1746710957405},"postHourTrading":{"tag":"盘后","latestPrice":283.77,"preClose":283.77,"latestTime":"19:58 EDT","volume":94871,"amount":26921818.4224,"timestamp":1746748722449},"volumeRatio":2.723402,"optionData":{"bulkOrders":[{"symbol":"COR","call":true,"expireDate":1747368000000,"strike":"300.0","timestamp":1746732387154,"price":2.55,"volume":3300,"amount":841500,"type":"+"},{"symbol":"COR","call":true,"expireDate":1747368000000,"strike":"320.0","timestamp":1746732387154,"price":0.55,"volume":3300,"amount":181500,"type":"-"}]},"impliedVol":0.2741,"impliedVolPercentile":0.808},"requestUrl":"/m/hq/s/COR","defaultTab":"news","newsList":[{"id":"2534163604","title":"花旗：维持Cencora(COR.US)评级，由买入调整至买入评级, 目标价由330.00美元调整至355.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534163604","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534163604?lang=zh_cn&edition=full","pubTime":"2025-05-09 03:23","pubTimestamp":1746732206,"startTime":"0","endTime":"0","summary":"花旗：维持Cencora(COR.US)评级，由买入调整至买入评级, 目标价由330.00美元调整至355.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09032350242871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COR"],"gpt_icon":0},{"id":"2533136866","title":"Cencora, Inc.跌1.60% 股价跌破300美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2533136866","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533136866?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:42","pubTimestamp":1746711771,"startTime":"0","endTime":"0","summary":"北京时间2025年05月08日21时42分，Cencora, Inc.股票出现异动，股价急速下挫1.60%。截至发稿，该股报299.71美元/股，成交量11.2051万股，换手率0.06%，振幅0.99%。Cencora, Inc.股票所在的医疗销售行业中，整体跌幅为0.64%。Cencora, Inc.公司简介：Cencora是美国三大领先的医药批发商之一。Cencora还为药品和医疗器械制造商、全球专科药品物流和动物保健产品分销提供商业化服务。Cencora于2021年通过收购欧洲领先的药品批发商之一Alliance Healthcare扩大了其国际业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508214252a6d7c667&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508214252a6d7c667&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","LU0289739699.SGD","LU2324357040.USD","LU1084165304.USD","LU1119994496.HKD","BK4175","SG9999004303.SGD","BK4529","BK4084","LU1430594728.SGD","LU2237957902.USD","SGXZ23171101.USD","BK4585","COR","BK4588","LU2237957811.SGD","LU1261432733.SGD","LU1585245621.USD"],"gpt_icon":0},{"id":"1120063298","title":"异动解读 | CENCORA盘中大涨5.06%，特药需求强劲推动业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120063298","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120063298?lang=zh_cn&edition=full","pubTime":"2025-05-07 22:12","pubTimestamp":1746627156,"startTime":"0","endTime":"0","summary":"美国药品分销巨头CENCORA今日盘中大涨5.06%，投资者对公司最新财报及上调全年利润预期表现出强烈信心。CENCORA公布的截至3月31日的第二季度调整后每股收益为4.42美元，远超分析师预期的4.11美元。数据显示，CENCORA第二季度总销售额达到754.5亿美元，同比增长10.3%。其中，美国医疗保健业务销售额增长11.4%至683亿美元，成为公司最大的收入来源。这一趋势反映了美国市场对治疗复杂疾病的高利润药品需求不断增长，为CENCORA及其同行带来了良好的发展机遇。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | CENCORA盘中大涨5.06%，特药需求强劲推动业绩超预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["COR"],"gpt_icon":0},{"id":"2532856675","title":"东吴证券：一季度可比口径下险企NBV继续较快增长 产险COR显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2532856675","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532856675?lang=zh_cn&edition=full","pubTime":"2025-05-02 09:26","pubTimestamp":1746149205,"startTime":"0","endTime":"0","summary":"平安可比口径下按首年保费计算NBV margin同比+11.4pct至28.3%，预计主要受产品结构改善、报行合一以及预定利率下调等因素影响。东吴证券主要观点如下：一季度上市险企归母净利润合计同比+1.4%，净资产增速表现显著分化1)2025Q1人保、国寿、新华归母净利润分别同比+43%、+39.5%、+19%，太保同比-18%。各公司NBV较快增长仍主要受NBV margin提升带动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1119994496.HKD","LU1430594728.SGD","601555","BK4084","BK4175","LU1585245621.USD","BK0009","BK0012","COR","BK4585","LU1261432733.SGD","BK4588","LU2237957902.USD","LU2324357040.USD","BK0028","SGXZ23171101.USD","BK0188","LU0289739699.SGD","BK0183","LU1084165304.USD","SG9999004303.SGD","BK0276","BK4529","LU0058720904.USD","LU2237957811.SGD"],"gpt_icon":0},{"id":"2513790918","title":"【研报掘金｜华泰证券：上调中国再保险目标价至1.1港元 去年盈利超预期】华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513790918","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513790918?lang=zh_cn&edition=full","pubTime":"2025-02-24 13:49","pubTimestamp":1740376141,"startTime":"0","endTime":"0","summary":"华泰证券发表研究报告指，中国再保险预计2024年归母净利润按年升80%至100%，超出该行预期。该行认为，公司利润高速增长，或主要受投资业绩高增以及保险业务稳健增长的驱动。该行预计，集团2024年人身再保险业务净利润有望增长236%，2024年全年财险业务COR达99.8%。该行表示，考虑到投资波动，将上年、今年及明年每股盈测上调至分别0.25元、0.21元及0.21元，目标价则由1港元上调至1.1港元，维持其评级为“买入”。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24134948338990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COR","06886","01508"],"gpt_icon":0},{"id":"2509764246","title":"【沃尔格林联合博姿继续出售Cencora股份 套现约3亿美元】 美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）","url":"https://stock-news.laohu8.com/highlight/detail?id=2509764246","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509764246?lang=zh_cn&edition=full","pubTime":"2025-02-07 14:41","pubTimestamp":1738910486,"startTime":"0","endTime":"0","summary":"美国连锁药店沃尔格林联合博姿周四表示，已出售更多药品分销商Cencora的股份，套现约3亿美元。该公司目前在Cencora的持股比例从10%降至6%。此次出售股份所得将主要用于偿还债务和一般公司用途。（智通财经）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07144148009324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4529","LU0321505439.SGD","LU2237957811.SGD","SG9999004303.SGD","LU0289739699.SGD","LU0321505868.SGD","BK4588","LU1084165304.USD","LU1585245621.USD","COR","BK4585","BK4084","SGXZ23171101.USD","LU1119994496.HKD","LU2324357040.USD","LU0058720904.USD","LU2237957902.USD","LU1430594728.SGD","WBA","BK4128","BK4175","LU1261432733.SGD"],"gpt_icon":0},{"id":"1126125390","title":"Cencora 第一季度财报：肥胖药物和特殊药品推动收入和每股收益超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1126125390","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126125390?lang=zh_cn&edition=full","pubTime":"2025-02-06 00:11","pubTimestamp":1738771872,"startTime":"0","endTime":"0","summary":"周三，Cencora, Inc公布其2025财年第一季度销售额增长12.8%，达到815亿美元，超过市场预期的783.8亿美元。公司报告的调整后每股收益为3.73美元，同比增长13.7%，超过市场预期的3.50美元。调整后的毛利润在2025年第一季度为25亿美元，比上一财年同期增长6.1%，这是由于两个报告部门的毛利润增加。Cencora预期调整后的摊薄每股收益为15.25至15.55美元，高于1月2日提供的15.15至15.45美元的范围以及最初的14.80至15.10美元的范围，市场预期为15.28美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR","MDCO"],"gpt_icon":0},{"id":"2509404970","title":"Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509404970","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509404970?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:46","pubTimestamp":1738755995,"startTime":"0","endTime":"0","summary":"Cencora(COR.US)：2025年Q1财报实现营收814.87亿美元，前值为722.53亿美元，预期值为782.2亿美元；每股收益为3.73美元，前值为3.28美元，预期值为3.52美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/05194647966049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COR"],"gpt_icon":0},{"id":"1158459761","title":"Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1158459761","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158459761?lang=zh_cn&edition=full","pubTime":"2025-02-05 19:32","pubTimestamp":1738755166,"startTime":"0","endTime":"0","summary":"Cencora 报告其季度每股收益为$3.73，超过分析师普遍预期的$3.50，超出6.57%。与去年同期每股收益$3.28相比增长了13.72%。以上内容来自Benzinga Earnings专栏，原文如下：Cencora reported quarterly earnings of $3.73 per share which beat the analyst consensus estimate of $3.50 by 6.57 percent. This is a 13.72 percent increase over earnings of $3.28 per share from the same period last year. The company reported quarterly sales of $81.49 billion which beat the analyst consensus estimate of $78.38 billion by 3.96 percent. This is a 12.78 percent increase over ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Cencora 2025年第一季度调整后每股收益$3.73，超过预期的$3.50，销售额为$814.9亿，超过预期的$783.8亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR"],"gpt_icon":0},{"id":"2507682115","title":"富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507682115","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507682115?lang=zh_cn&edition=full","pubTime":"2025-01-29 19:53","pubTimestamp":1738151599,"startTime":"0","endTime":"0","summary":"富国银行：维持Cencora(COR.US)评级，由持股观望调整至持股观望评级, 目标价由237.00美元调整至251.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/29195347897048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["COR"],"gpt_icon":0},{"id":"2490834879","title":"新旧会计准则切换：保险公司利润瞬间“变脸” 从巨亏10.87亿元到大赚11.11亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490834879","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490834879?lang=zh_cn&edition=full","pubTime":"2024-12-12 15:56","pubTimestamp":1733990160,"startTime":"0","endTime":"0","summary":" 交银人寿今年三季度交出了两份截然不同的财报，一份巨亏10.87亿元，一份大赚11.11亿元，二者差值高达21.98亿元。 值得注意的是，三季度偿付能力报告中，交银人寿仅以新准则编制净利润和保险合同负债，其余数据仍使用“旧准则”，因此，其保险业务收入保持一致。 其中，人保寿险最新披露的两份三季报显示，使用新准则计量得到的利润比旧准则下的利润高出131.19亿元，而保险业务收入则缩水了798.83亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxdt/2024-12-12/doc-inczeuyp3020376.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2024-12-12/doc-inczeuyp3020376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4175","BK4585","ZTmain","LU0289739699.SGD","TNmain","BK4529","ZNmain","HTM","ZBmain","BK4135","LU1119994496.HKD","SG9999004303.SGD","LU1585245621.USD","LU1261432733.SGD","BK4084","UBmain","LU0058720904.USD","AC","LU1084165304.USD","LU1430594728.SGD","LU2324357040.USD","ZFmain","SGXZ23171101.USD","COR"],"gpt_icon":0},{"id":"2485415552","title":"中国人保：COR承压NBV翻倍 投资拉动利润高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2485415552","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485415552?lang=zh_cn&edition=full","pubTime":"2024-11-21 21:30","pubTimestamp":1732195856,"startTime":"0","endTime":"0","summary":"前三季度，中国人保持续优化业务结构，强化风险防控，财险领先地位稳固，寿险NBV增速亮眼，投资端带动利润高增，看好权益市场回暖下的业绩表现。本刊特约 方斐/文中国人保发布的2024三季报显示，报告期内，公司实现营业总收入4695.8亿元，同比增长12.2%；实现归母净利润363.3亿元，同比增长77.2%。财险综合成本率（COR）为...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/Owtnm3wVFyOx_qdkAU-tOo4dGazjncNBodXMBIbagy_voAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/Owtnm3wVFyOx_qdkAU-tOo4dGazjncNBodXMBIbagy_voAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241121A09I7K00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241121A09I7K00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["SGXZ23171101.USD","BK4585","BK4084","BK4588","BK4175","LU1084165304.USD","LU1119994496.HKD","LU1430594728.SGD","LU1585245621.USD","LU0058720904.USD","LU0289739699.SGD","COR","BK4529","LU1261432733.SGD","SG9999004303.SGD","LU2324357040.USD"],"gpt_icon":0},{"id":"2483038304","title":"Cencora, Inc.2024财年实现净利润15.09亿美元，同比减少13.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483038304","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483038304?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:00","pubTimestamp":1731600044,"startTime":"0","endTime":"0","summary":"11月15日，Cencora, Inc.公布财报，公告显示公司2024财年净利润为15.09亿美元，同比减少13.52%；其中营业收入为2,939.59亿美元，同比增加12.12%，每股基本收益为7.60美元。从资产负债表来看，Cencora, Inc.总负债663.15亿美元，其中短期债务5.76亿美元，资产负债比为1.02，流动比率为0.88。机构评级：截至2024年11月15日，当前有15家机构对Cencora, Inc.目标价做出预测，其中目标均价为272.00美元，其中最低目标价为240.00美元，最高目标价为292.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000100abc188aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000100abc188aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["COR"],"gpt_icon":0},{"id":"2481980584","title":"Cencora, Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481980584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481980584?lang=zh_cn&edition=full","pubTime":"2024-11-07 00:15","pubTimestamp":1730909711,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日00时15分，Cencora, Inc.股票出现波动，股价大幅上涨5.00%。Cencora, Inc.股票所在的医疗销售行业中，整体涨幅为3.65%。Cencora, Inc.公司简介：Cencora Inc 是其国内三大领先的医药批发商之一。Cencora于2021年通过收购欧洲领先的药品批发商之一Alliance Healthcare扩大了其国际业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107001512971a4d5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241107001512971a4d5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2324357040.USD","BK4588","BK4529","LU0289739699.SGD","LU1261432733.SGD","COR","LU1084165304.USD","LU1430594728.SGD","SG9999004303.SGD","SGXZ23171101.USD","BK4585","LU1119994496.HKD","LU1585245621.USD","BK4175","BK4084","LU0058720904.USD"],"gpt_icon":0},{"id":"2479217561","title":"【券商聚焦】国联证券维持中国财险(02328)“买入”评级 料车险执行“报行合一”有望带动COR同比改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2479217561","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479217561?lang=zh_cn&edition=full","pubTime":"2024-10-30 12:24","pubTimestamp":1730262269,"startTime":"0","endTime":"0","summary":"车险COR延续向好，预计主要系车险执行“报行合一”推动费用率同比改善；非车险COR同比有所抬升，预计主要系大灾损失同比增加。该行续指，考虑到车险执行“报行合一”以及公司加强风险管控有望带动COR同比改善、权益市场回暖有望带动投资收益同比正增，该行预计公司2024-2026年归母净利润分别为339/357/398亿，对应增速分别为38%/6%/11%。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/ZjFkNmRhNDdmNGNlNWE2NWI4ZjM1ZDNmNTg4YjM5OTg4NDI0NTU0Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1946764","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR","01456","601456","02328"],"gpt_icon":0},{"id":"2479138552","title":"里昂：升中国财险目标价至15.2港元 第三季业绩好坏参半","url":"https://stock-news.laohu8.com/highlight/detail?id=2479138552","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479138552?lang=zh_cn&edition=full","pubTime":"2024-10-30 10:46","pubTimestamp":1730256377,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4175","IE00BWDBJ730.SGD","LU2476274308.USD","LU0327786744.USD","LU1084165304.USD","BK4585","LU1981816686.USD","LU1585245621.USD","399300","COR","LU0289739699.SGD","LU2778985437.USD","LU0058720904.USD","BK4084","07226","02328","HSTECH","IE00B19Z5X02.USD","BK1550","IE00BQJZWZ67.USD","LU1119994496.HKD","SGXZ23171101.USD","SG9999004303.SGD","YANG","LU1430594728.SGD","LU2488822045.USD","HSCEI","BK4529","BK1127","LU1261432733.SGD","BK4588","159982","LU2324357040.USD","LU0572944931.SGD"],"gpt_icon":0},{"id":"2475868740","title":"Cencora, Inc.盘中异动 急速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475868740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475868740?lang=zh_cn&edition=full","pubTime":"2024-10-15 22:39","pubTimestamp":1729003175,"startTime":"0","endTime":"0","summary":"北京时间2024年10月15日22时39分，Cencora, Inc.股票出现波动，股价快速上涨5.02%。Cencora, Inc.股票所在的医疗销售行业中，整体涨幅为2.75%。其相关个股中，Cencora, Inc.、麦克森、欧麦斯-麦能医疗涨幅较大，Cencora, Inc.、亨利香恩服务、麦克森较为活跃，换手率分别为0.43%、0.20%、0.19%，振幅较大的相关个股有1药网、Cencora, Inc.、Edap Tms S.A.，振幅分别为15.29%、4.97%、4.63%。Cencora, Inc.公司简介：Cencora Inc 是其国内三大领先的医药批发商之一。Cencora于2021年通过收购欧洲领先的药品批发商之一Alliance Healthcare扩大了其国际业务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101522393598e3c90e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101522393598e3c90e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","COR","LU1261432733.SGD","BK4585","LU0058720904.USD","SGXZ23171101.USD","LU1585245621.USD","BK4529","LU1430594728.SGD","SG9999004303.SGD","BK4175","LU0289739699.SGD","LU2324357040.USD","LU1084165304.USD","LU1119994496.HKD","BK4084"],"gpt_icon":0},{"id":"2468699475","title":"华创证券：下半年人身险NBV增长逻辑或有量价双驱机会 财险COR或同比好转","url":"https://stock-news.laohu8.com/highlight/detail?id=2468699475","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468699475?lang=zh_cn&edition=full","pubTime":"2024-09-20 14:30","pubTimestamp":1726813844,"startTime":"0","endTime":"0","summary":"2024H1人身险均受益于价值率改善，NBV实现较好增长；财产险受自然灾害加剧有所承压，但部分险企如太保、财险依旧逆势实现COR优化。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/source/image/77206.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/77206.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1185084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4084","SG9999004303.SGD","LU1084165304.USD","LU0058720904.USD","BK4588","LU1261432733.SGD","BK4175","SGXZ23171101.USD","161027","LU1585245621.USD","LU0289739699.SGD","COR","BK4585","LU1119994496.HKD","LU1430594728.SGD","BK4529"],"gpt_icon":0},{"id":"2468654595","title":"【券商聚焦】国联证券维持中国财险(02328)“买入”评级 指COR有望延续向好","url":"https://stock-news.laohu8.com/highlight/detail?id=2468654595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468654595?lang=zh_cn&edition=full","pubTime":"2024-09-19 09:09","pubTimestamp":1726708149,"startTime":"0","endTime":"0","summary":"对于车险COR，随着公司持续升级风险减量服务水平、优化车险业务结构，公司的车险赔付率有望改善。叠加监管引导车险理性竞争带动费用率改善，该行预计公司2024年的车险COR有望改善至97%以下。该行表示，鉴于公司持续注重高质量发展、坚持效益优先，2024年公司的COR有望延续向好。鉴于公司稀缺的商业模式和较高的ROE，该行维持“买入”评级。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200915/NDVmZWE2ZWUwNjY0MTYwMDE0OTY1ODIwOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NDVmZWE2ZWUwNjY0MTYwMDE0OTY1ODIwOA==.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1944454","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COR","02328","01456","601456"],"gpt_icon":0},{"id":"2468487586","title":"【金色晚报 | 9月18日晚间重要动态一览】12:00-21:00关键词：Revolut、MicroStrategy、贝","url":"https://stock-news.laohu8.com/highlight/detail?id=2468487586","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468487586?lang=zh_cn&edition=full","pubTime":"2024-09-18 21:00","pubTimestamp":1726664426,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"'https://api.jinse.com/noah/v2/lives","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["DYDX.USD.HKCC","DOT.USD.CC","09008","FBTC","GBTC","HK0000934320.USD","HODL","TON.USD.HKCC","UNI.USD.HKCC","VBTC.AU","AVAX.USD.CC","MKR.USD.CC","COMP.USD.CC","03042","SNX.USD.CC","SNX.USD.HKCC","09042","COR","SPY","DOT.USD.HKCC","BTC.USD.HKCC","MATIC.USD.HKCC","BRRR","DEFI","MATIC.USD.CC","UNI.USD.CC","BITO","LINK.USD.HKCC","BTCW","US30Y.BOND","US12M.BOND","MSTX","APT.USD.HKCC","BLK","APT.USD.CC","US10Y.BOND","LTC.USD.HKCC","EZBC","03008","ATOM.USD.HKCC","BTCO","US3Y.BOND","IBIT","LDO.USD.HKCC","US7Y.BOND","COIN","TON.USD.CC","RNDR.USD.HKCC","USDT.USD.CC","COMP.USD.HKCC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cencora.com","stockEarnings":[{"period":"1week","weight":0.0407},{"period":"1month","weight":0.1093},{"period":"3month","weight":0.2375},{"period":"6month","weight":0.2261},{"period":"1year","weight":0.3433},{"period":"ytd","weight":0.3556}],"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.1126},{"period":"3month","weight":-0.0745},{"period":"6month","weight":-0.0619},{"period":"1year","weight":0.0851},{"period":"ytd","weight":-0.0425}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cencora, Inc.是全球最大的药品采购和分销服务公司之一，帮助医疗保健供应商以及制药和生物技术制造商改善患者获得产品加强患者护理的机会。该公司提供创新计划和服务，旨在提高药品供应链在人类和动物健康方面的效力和效率。更具体地说，该公司向位于美国和部分全球市场的各种医疗保健提供商提供全面的品牌、专业品牌和非专利药品、非处方医疗产品、家庭医疗用品和设备以及相关服务，包括急性病医院和卫生系统、独立和连锁零售药店、邮购药房、诊所、长期护理和替代地点药房、医师执业、医疗和透析诊所、兽医和其他客户。此外，公司还为医疗保健提供商和制药制造商提供各种相关服务，包括数据分析、结果研究、报销和药物咨询服务、利基优质物流服务、库存管理、药房自动化、药房管理和包装解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.793103,"avgChangeRate":0.049548},{"month":2,"riseRate":0.551724,"avgChangeRate":-0.002452},{"month":3,"riseRate":0.586207,"avgChangeRate":0.009147},{"month":4,"riseRate":0.586207,"avgChangeRate":0.016375},{"month":5,"riseRate":0.655172,"avgChangeRate":0.025748},{"month":6,"riseRate":0.517241,"avgChangeRate":0.029089},{"month":7,"riseRate":0.586207,"avgChangeRate":0.014597},{"month":8,"riseRate":0.586207,"avgChangeRate":-0.010675},{"month":9,"riseRate":0.517241,"avgChangeRate":0.023105},{"month":10,"riseRate":0.551724,"avgChangeRate":-0.00923},{"month":11,"riseRate":0.689655,"avgChangeRate":0.030742},{"month":12,"riseRate":0.551724,"avgChangeRate":0.017093}],"exchange":"NYSE","name":"CENCORA","nameEN":"Cencora Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CENCORA(COR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供CENCORA(COR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"CENCORA,COR,CENCORA股票,CENCORA股票老虎,CENCORA股票老虎国际,CENCORA行情,CENCORA股票行情,CENCORA股价,CENCORA股市,CENCORA股票价格,CENCORA股票交易,CENCORA股票购买,CENCORA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CENCORA(COR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供CENCORA(COR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}